Author Login

Correspondence to Author: Júlio Elias Calheiros¹,Beatriz de Luna Costa Pinheiro¹⁰,Maurício Martinez Puglia¹¹, Anderson Paulo de Oliveira¹, Ana Luiza Zampar Quintana Gomes⁹, Aline Cristina Couto da Silva¹, Délio Tiago Martins Malaquias^1-4, Érica Miriam Fernandes M. Vao¹, Leonardo Tomé da Silva¹, Victor Rodrigues de Paula¹, Wellington da Silva Pereira da Cunha¹, José Carlos Ferreira da Silva¹, Gabriel Urquiza Carvalho³, Giovana Casarini Yamashiro³, Ana Laura Nogueira Ervilha⁵, Victoria Cristina Galbes Moretti⁶, Bárbara Leitão⁶, Giovana Barreto Lima de Oliveira ⁶, Rubens Rodrigues Tudela⁷, Cristiano Bento Alvarenga², Joel Eloi Belo Junior¹², Thiago Augusto Rochetti Bezerra^1-8. 

1. Medical student. University of Ribeirão Preto (UNAERP). Guarujá, São Paulo, Brazil.
2. Medical Student (UCP). Central University of Paraguay. C iudad del Este. Paraguay.
3. Medical student. Nove de Julho University, São Bernardo do Campo, São Paulo, Brazil.
4. Graduated in Physiotherapy from the University of Mogi das Cruzes; Postgraduate in Respiratory Physiotherapy and Pediatric Intensive Care and Neonatology from the University of São Paulo, São Paulo/SP, Hospital Physiotherapy, Bahiana School of Medicine and Public Health. Salvador/BA. Brazil.
5. Medical student. Humanitas - Faculty of Medical Sciences in São José dos Campos. São Paulo, Brazil.
6. Medical student. Professor Franco Montoro Municipal College. Mogi Guaçu, São Paulo, Brazil.
7. Medical student. São Judas Tadeu. Cubatão, São Paulo, Brazil.
8. PhD in Medical Sciences. University of São Paulo (USP). Ribeirão Preto Medical School. São Paulo, Brazil.
9. Medical student. University Prof. Edson Antônio Velano. Unifenas, Alfenas, Minas Gerais, Brazil
10. Medical graduate from the Nove de Julho University (UNINOVE). São Paulo, Brazil. Postgraduate student in Dematology.
11. Medical graduate from the Nove de Julho University (UNINOVE). São Paulo, Brazil.
12. Master’s degree in Operational Human Performance. Master’s student in Intellectual Property and Technology Transfer for Innovation.

DOI: 10.52338/jodld.2025.4714

Abstract:

Inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic diseases of the gastrointestinal tract characterized by recurrent inflammation, significant functional impact and impaired quality of life. The treatment of these diseases has undergone important advances in recent decades, especially with the introduction of biological therapies. This study aimed to carry out a systematic review of the literature on the efficacy and safety of biological therapies in the management of CD and CRU. The search was carried out in the PubMed, SciELO, LILACS, Embase and Web of Science databases, resulting in the inclusion of 37 studies published between 2013 and 2024. The results showed that anti-TNF agents (infliximab, adalimumab, among others) are the most widely used and widely studied, with consolidated efficacy in inducing and maintaining remission. However, therapeutic failures associated with immunogenicity are common. Vedolizumab and ustekinumab have emerged as effective options with a favorable safety profile. JAK inhibitors, such as tofacitinib, have shown good results in CR, although they require greater vigilance due to potential adverse effects. The discussion highlighted the importance of a personalized approach, guided by treat-to-target strategies and the use of biomarkers. It is concluded that biological therapies have revolutionized the treatment of IBD, but the appropriate choice requires careful clinical evaluation, continuous monitoring and equitable access to technologies.

Keywords:Crohn’s disease. Ulcerative colitis. Inflammatory Bowel Diseases. Biological therapies. Anti-TNF. Vedolizumab. Ustekinumab. Tofacitinib.

Citation:

Dr.Thiago Augusto Inflammatory Bowel Diseases (*DIIS) Therapies Biologics For The Management Of Crohn’s Disease And *Ulcerative Colitis. Journal of Digestive and Liver Diseases 2025.